1. Home
  2. TRVI vs PFN Comparison

TRVI vs PFN Comparison

Compare TRVI & PFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRVI
  • PFN
  • Stock Information
  • Founded
  • TRVI 2011
  • PFN 2004
  • Country
  • TRVI United States
  • PFN United States
  • Employees
  • TRVI N/A
  • PFN N/A
  • Industry
  • TRVI Biotechnology: Pharmaceutical Preparations
  • PFN Finance/Investors Services
  • Sector
  • TRVI Health Care
  • PFN Finance
  • Exchange
  • TRVI Nasdaq
  • PFN Nasdaq
  • Market Cap
  • TRVI 725.7M
  • PFN 636.0M
  • IPO Year
  • TRVI 2019
  • PFN N/A
  • Fundamental
  • Price
  • TRVI $6.89
  • PFN $7.38
  • Analyst Decision
  • TRVI Strong Buy
  • PFN
  • Analyst Count
  • TRVI 9
  • PFN 0
  • Target Price
  • TRVI $19.94
  • PFN N/A
  • AVG Volume (30 Days)
  • TRVI 1.6M
  • PFN 331.7K
  • Earning Date
  • TRVI 08-07-2025
  • PFN 01-01-0001
  • Dividend Yield
  • TRVI N/A
  • PFN 11.66%
  • EPS Growth
  • TRVI N/A
  • PFN N/A
  • EPS
  • TRVI N/A
  • PFN N/A
  • Revenue
  • TRVI N/A
  • PFN N/A
  • Revenue This Year
  • TRVI N/A
  • PFN N/A
  • Revenue Next Year
  • TRVI N/A
  • PFN N/A
  • P/E Ratio
  • TRVI N/A
  • PFN N/A
  • Revenue Growth
  • TRVI N/A
  • PFN N/A
  • 52 Week Low
  • TRVI $2.36
  • PFN $5.94
  • 52 Week High
  • TRVI $7.48
  • PFN $7.58
  • Technical
  • Relative Strength Index (RSI)
  • TRVI 64.54
  • PFN 54.00
  • Support Level
  • TRVI $5.41
  • PFN $7.35
  • Resistance Level
  • TRVI $6.08
  • PFN $7.54
  • Average True Range (ATR)
  • TRVI 0.32
  • PFN 0.04
  • MACD
  • TRVI 0.14
  • PFN -0.00
  • Stochastic Oscillator
  • TRVI 89.91
  • PFN 49.73

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

About PFN PIMCO Income Strategy Fund II

PIMCO Income Strategy Fund II is a closed-ended fixed income mutual fund. The company's primary investment objective is to seek high current income, consistent with the preservation of capital. The fund invests in a range of securities, such as corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, municipal bonds and notes, short-term instruments, sovereign Issues, preferred Securities and others.

Share on Social Networks: